The Therapeutic Goods Administration (TGA) has released its latest list of decisions relating to Australian manufacturers licensed to produce therapeutic goods, outlining new manufacturing approvals alongside changes to existing licences as part of its ongoing regulatory oversight.
According to the TGA, the update reflects decisions made under Section 38 of the Therapeutic Goods Act 1989, which governs the granting of licences for the manufacture of medicines, biologicals, and other therapeutic products in Australia.
The most recent publication shows that 14 manufacturing licences have been granted, two licences have been suspended, and eight licences have been revoked, as part of routine regulatory action aimed at ensuring compliance with Australia’s manufacturing standards for therapeutic goods.
The list of newly granted licences includes a range of manufacturers operating across pharmaceuticals, logistics, laboratory services, and advanced biotechnology sectors. Among those approved are Biomecentric Pty Ltd in Queensland, Vaxxas Pty Ltd also based in Queensland, Medsurge Healthcare Pty Ltd in Victoria, and Syntro Health in Melbourne.
Other newly licensed entities include PharmaCrop Pty Ltd, Apex Labs Pty Ltd, and AdvanCell Pty Limited, reflecting a broad spread of manufacturing activity across multiple states.
The TGA also confirmed approvals for organisations involved in logistics and specialised health services, including DHL Supply Chain Australia Pty Limited and the Australian Red Cross Lifeblood service, which operates blood collection and processing facilities.
All licensing decisions are part of the regulator’s broader responsibility to ensure that therapeutic goods manufactured in Australia meet required standards of safety, quality, and efficacy before being supplied to the public. The TGA emphasises that manufacturing licences remain valid unless suspended or revoked and are subject to ongoing compliance monitoring.
Manufacturers are also required to meet strict conditions relating to production processes, quality assurance, and compliance with Good Manufacturing Practice (GMP) standards, with the regulator retaining the authority to take enforcement action where requirements are not met.
The TGA continues to publish licence decisions on its website as part of its transparency framework, allowing public access to updates on manufacturing approvals and regulatory changes within Australia’s therapeutic goods sector.
